Montag & Caldwell LLC decreased its holdings in shares of Celgene Corporation (NASDAQ:CELG) by 26.4% in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 793,193 shares of the biopharmaceutical company’s stock after selling 284,071 shares during the period. Celgene Corporation makes up 3.0% of Montag & Caldwell LLC’s holdings, making the stock its 18th largest position. Montag & Caldwell LLC owned 0.10% of Celgene Corporation worth $103,012,000 as of its most recent SEC filing.
Other institutional investors have also modified their holdings of the company. Harel Insurance Investments & Financial Services Ltd. bought a new stake in shares of Celgene Corporation during the 1st quarter valued at $118,000. Acropolis Investment Management LLC acquired a new position in shares of Celgene Corporation in the 2nd quarter valued at $144,000. Mitsubishi UFJ Securities Holdings Co. Ltd. grew its holdings in shares of Celgene Corporation by 47.5% in the 1st quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,180 shares of the biopharmaceutical company’s stock valued at $147,000 after buying an additional 380 shares during the period. Oakworth Capital Inc. grew its holdings in shares of Celgene Corporation by 11.7% in the 2nd quarter. Oakworth Capital Inc. now owns 1,216 shares of the biopharmaceutical company’s stock valued at $158,000 after buying an additional 127 shares during the period. Finally, Smithfield Trust Co. grew its holdings in shares of Celgene Corporation by 35.7% in the 2nd quarter. Smithfield Trust Co. now owns 1,229 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 323 shares during the period. Institutional investors own 79.36% of the company’s stock.
In other Celgene Corporation news, Director Gilla Kaplan sold 9,250 shares of the business’s stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total value of $1,309,430.00. Following the completion of the transaction, the director now owns 85,551 shares of the company’s stock, valued at approximately $12,110,599.56. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Terrie Curran sold 1,727 shares of the business’s stock in a transaction that occurred on Monday, September 25th. The stock was sold at an average price of $143.89, for a total transaction of $248,498.03. Following the completion of the transaction, the insider now directly owns 3,925 shares of the company’s stock, valued at approximately $564,768.25. The disclosure for this sale can be found here. In the last three months, insiders sold 46,233 shares of company stock valued at $6,268,259. Corporate insiders own 0.95% of the company’s stock.
Several equities analysts have recently issued reports on CELG shares. Morgan Stanley lowered shares of Celgene Corporation from an “equal weight” rating to an “underweight” rating and set a $120.00 price target for the company. in a report on Thursday, October 5th. Leerink Swann raised shares of Celgene Corporation from a “market perform” rating to an “outperform” rating and boosted their price target for the company from $94.42 to $150.00 in a report on Friday, June 16th. They noted that the move was a valuation call. William Blair reissued an “outperform” rating on shares of Celgene Corporation in a report on Monday, June 26th. Cantor Fitzgerald reissued a “buy” rating on shares of Celgene Corporation in a report on Monday, August 28th. Finally, BTIG Research lowered shares of Celgene Corporation from a “buy” rating to a “neutral” rating and boosted their price target for the company from $96.93 to $131.70 in a report on Friday, June 30th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and twenty-two have assigned a buy rating to the stock. Celgene Corporation presently has a consensus rating of “Buy” and an average target price of $150.60.
TRADEMARK VIOLATION WARNING: “Montag & Caldwell LLC Sells 284,071 Shares of Celgene Corporation (CELG)” was published by Stock Observer and is owned by of Stock Observer. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international trademark and copyright law. The original version of this piece of content can be read at https://www.thestockobserver.com/2017/10/13/montag-caldwell-llc-sells-284071-shares-of-celgene-corporation-celg.html.
Celgene Corporation (NASDAQ CELG) opened at 138.50 on Friday. Celgene Corporation has a one year low of $96.93 and a one year high of $147.17. The company has a market capitalization of $108.36 billion, a PE ratio of 42.89 and a beta of 1.88. The stock’s 50 day moving average is $140.52 and its 200 day moving average is $129.98.
Celgene Corporation (NASDAQ:CELG) last released its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 EPS for the quarter, topping the Zacks’ consensus estimate of $1.61 by $0.21. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The business had revenue of $3.27 billion during the quarter, compared to analysts’ expectations of $3.23 billion. During the same quarter in the previous year, the company earned $1.44 EPS. The business’s quarterly revenue was up 18.7% compared to the same quarter last year. On average, analysts anticipate that Celgene Corporation will post $7.33 earnings per share for the current fiscal year.
About Celgene Corporation
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.